Haemonetics Beats Q4 Estimates but Gross Margin Weakness Clouds Outlook

What happened

Haemonetics reported fiscal Q4 earnings and revenue above consensus, driving a modest 1.4% share gain. However, gross margin contracted 120 basis points, underscoring persistent cost headwinds. The company also issued its FY27 growth outlook, which management framed positively but lacks specificity on the critical CSL Plasma transition. The beat was anticipated given the Hospital segment's momentum, but the margin degradation signals that portfolio pruning and operational efficiencies have not yet translated to profitability improvement. The combined picture leaves the investment case balanced: solid Hospital execution is offset by Plasma uncertainty and margin compression.

Implication

The underlying Hospital strength and buyback support provide a floor, but sustained margin improvement and clarity on Plasma stabilization are needed for multiple expansion. Investors should require evidence of gross margin recovery and a credible path through the CSL trough before turning constructive.

Thesis delta

The Q4 beat was overshadowed by a 120 bps gross margin decline, confirming near-term profitability pressure not fully captured in the Master Report's neutral stance. This elevates the importance of margin trends as a key variable, tilting the risk-reward slightly more cautious until management demonstrates cost control and Plasma stabilization.